PLAU and breast cancer: To directly evaluate the functional relevance of uPA‐PAI‐1 heteromerization for the trafficking of pro‐tumorigenic neutrophils in breast cancer, we tested the compound WX‐340, a novel small‐molecule inhibitor that competitively interferes with the binding of uPA to PAI‐1.